about
Autoimmune dementia: clinical course and predictors of immunotherapy responseHumoral pattern II multiple sclerosis pathology not associated with neuromyelitis Optica IgGDPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients.Neuromyelitis optica spectrum disorders in children and adolescents.Childhood onset of stiff-man syndrome.Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy.Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures.Seizure versus syncope.Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study.Immunotherapy trial as diagnostic test in evaluating patients with presumed autoimmune gastrointestinal dysmotility.Autoimmune epilepsy: clinical characteristics and response to immunotherapyInsights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping.AQP4 autoantibody assay performance in clinical laboratory service.The neurologic significance of celiac disease biomarkersSerologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disordersMetabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes.Paraneoplastic and other autoimmune disorders of the central nervous system.Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica.Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum DisorderNeurological autoimmunity targeting aquaporin-4.Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitisIgLON5 antibody: Neurological accompaniments and outcomes in 20 patients.Microtubule-associated protein 1B: Novel paraneoplastic biomarker.Psychiatric Autoimmunity: N-Methyl-D-Aspartate Receptor IgG and Beyond.Autoimmune Encephalitis in the ICU: Analysis of Phenotypes, Serologic Findings, and Outcomes.Repetitive exercise dystonia: A difficult to treat hazard of runner and non-runner athletes.Autoimmune Encephalopathies and Dementias.Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis.[A low back pain revealing a stiff-man syndrome].Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients.Autoimmune Movement Disorders: a Clinical and Laboratory Approach.Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients.Predictive models in the diagnosis and treatment of autoimmune epilepsy.Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum.Opsoclonus-Myoclonus Syndrome during Rituximab Treatment for Autoimmune Autonomic Ganglionopathy.
P50
Q24597504-36A0EB05-8652-4685-9B4E-4EB1F43003C2Q24648929-37BC48D5-1903-4263-937B-E54B5C256599Q27312074-07BD806E-4AAF-4996-858C-D5D43AB38346Q30248246-182309E8-F2A3-4E2B-AC00-E352D952DDB0Q30386799-FA5A420F-0244-41F9-8C44-15A1B3A88FD7Q30577078-0149CEA0-E667-4664-BCBA-41B564983A51Q30577655-B24EBF25-875E-4FB4-98A1-79DCCCCFF546Q30666620-D7F51E4E-B4B8-411C-96CB-B531E56D19C8Q33153508-66CC8966-4249-4B16-A99B-172485B0C7D1Q34088519-CC70D331-F530-4B9A-A62C-2EC63FB406DBQ34111688-D5E7053C-8090-4CFB-AC49-4C404FDF840AQ34263857-D0864896-83F0-4F85-A381-007E9A61A5F8Q34327732-8E1A876D-2817-42F3-90B6-897C6A4583E3Q34368662-97D2CA8C-B6F0-4314-84B9-71B2A3254E4DQ34556510-D1AE57AC-C1CA-4D4E-8D5E-73BD8EB5E7F1Q35776490-FEB36E70-68FE-4EE5-B5B3-29795727A4ACQ36002919-71309920-4A05-4A5A-8265-B1A8DA21220EQ36706020-035CCB7C-C83A-4BD1-B438-134901926F08Q37052800-3EF87FA6-5E5D-4B1E-AF62-6215513CEC1DQ37227096-34A09D8F-F46B-462D-B479-7A03849B53E6Q37250508-90DE922F-0805-4949-81FB-0BDA7417C382Q37584448-B6EFD0BB-5BA7-4A47-9935-81333737E1CFQ37601803-C99DB6DA-3FE2-4182-B36B-F733381421ABQ38372686-F790CADB-3DE2-4076-9EDB-2C1820C6ED48Q38376430-C8E62D77-A935-458D-99C6-6BFC9728F544Q38480914-928117DD-0F49-4C4E-B5DE-42276A45EBB6Q38576199-16DDF821-0C63-4583-B26B-BF325AD64FF4Q38789999-10BE21F8-5210-4575-B9A3-676939F11FCBQ38797586-181432C6-CEDF-48ED-8BA8-AB084FECF1AEQ38952082-F4B0B800-5449-4C7D-9368-493B2586F8D4Q38953401-0F65FFC8-253C-43E9-9897-309BD58453FEQ39000743-245936FD-FB22-4C42-9DC5-8694BDD69469Q39102143-C5DB657B-9FDB-459C-AA48-CB6166E5AA0EQ39796142-31FD0B42-6A8A-406A-950F-E8496D495B31Q39799856-6B3DBBBD-1E26-46CD-99B9-E465CF6BBA0BQ40154528-EF6D7F5B-B148-4431-A70F-F53E30280B71Q40181332-8017EDDC-36B3-41F0-BB40-1AFA7EB2EE92Q40492030-DBBA89BD-BDE7-431E-AEC6-5CCF4DC5D0CEQ40902234-0855BB0E-F494-4278-A4BD-C3EDA690BFA9Q40993874-C289096C-C375-4789-940F-460E8B88A85E
P50
description
investigador
@es
researcher
@en
name
Andrew McKeon
@en
type
label
Andrew McKeon
@en
prefLabel
Andrew McKeon
@en
P31
P496
0000-0001-6856-8143